Healthcare Industry Developments | BioTuesdays by Kilmer Lucas IR

Developments

First New Mexico Hospital leverages Perimeter’s AI-driven, wide field OCT margin visualization technology during breast cancer surgery

Perimeter Medical Imaging AI (TSX-V:Pink; OTC:PYNKF) announced that CHRISTIS St. Vincent is the first hospital in New Mexico to use its optical coherence technology (OCT), S-Series OCT, to visualize tissue margins...

February 19, 2025

Developments

Theratechnologies resumes U.S. supply of EGRIFTA SV for HIV

Theratechnologies (TSX:TH; NASDAQ:THTX) announced that the FDA has granted approval for the company to resume U.S. distribution of its tesamorelin injection, EGRIFTA SV, for patients with HIV. According to the company...

February 14, 2025

Developments

Medicus provides update on Phase 2 study of D-MNA in BCC

Medicus Pharma (NASDAQ:MDCX) announced that its SKNJCT-003 Phase 2 study, evaluating the efficacy of two dose levels of D-MNA for the treatment of nodular basal cell carcinoma (BCC), has now randomized more than 50% of...

February 14, 2025

Developments

Pliant assembles expert panel to review bexotegrast trial data in IPF

Pliant Therapeutics (NASDAQ:PLRX) announced that, following a recommendation by the Data Safety Monitoring Board (DSMB), it will convene an independent panel of experts in pulmonary diseases and biostatistics to review...

February 13, 2025

Developments

Top-tier journal publishes NKGen’s trial results on troculeucel in AD

NKGen Biotech (NASDAQ:NKGN) announced that results from its initial dose-escalation Phase 1 trial of troculeucel for the treatment of Alzheimer’s disease (AD) have been published in the international, peer-reviewed...

February 13, 2025

Developments

Top-tier journal describes unique properties of Aclaris’ ATI-2138

Aclaris Therapeutics (NASDAQ:ACRS) has announced that a publication in The Journal of Pharmacology and Experimental Therapeutics describes the unique properties its investigational drug, ATI-2138, which is in...

February 12, 2025

Developments

Windtree highlights abstract on istaroxime presented at 2025 THT conference

Windtree Therapeutics (NasdaqCM:WINT) has announced that an abstract discussing the positive results of SEISMiC, its Phase 2b study of istaroximine in cardiogenic shock, was presented by Dr. Matteo Pagnesi, a...

February 12, 2025

Developments

FOX 26 interview with Baylor’s Alastair Thompson discusses achieving clear margins in breast cancer surgery with Perimeter’s investigational B-Series OCT with ImgAssist AI 2.0

A FOX26 news interview featuring Dr. Alastair Thompson, a surgical oncologist at Baylor College of Medicine and the lead principal investigator of Perimeter Medical Imaging AI’s (TSX: PINK; OTC: PYNKF) pivotal trial on...

February 11, 2025

Developments

Firefly accepted into NVIDIA Connect program

Firefly Neuroscience (NASDAQ:AIFF) has announced its acceptance into the NVIDIA Connect program, granting access to advanced software development resources, frameworks, software development kits, and a global ecosystem...

February 11, 2025

Developments

Eledon’s tegoprubart plays key role in recent GM pig kidney transplant

Eledon Pharmaceuticals (NASDAQ:ELDN) has announced that its investigational anti-CD40L antibody, tegoprubart, was used as a key component of the immunosuppression therapy regimen in a patient who recently received a...

February 11, 2025

Developments

OIO grants HEALWELL regulatory approval to acquire Orion Health

HEALWELL AI (TSX:AIDX; QTCQX:HWAIF) has announced that New Zealand’s Overseas Investment Office (OIO) has granted consent for the company to acquire all ordinary shares of Orion Health, based in Auckland, New Zealand...

February 10, 2025

Developments

Medincell reports completion of Phase 3 trial of olanzapine LAI in schizophrenia

Medincell (EPA:MEDCL) has announced the completion of SOLARIS, its Phase 3 trial of olanzapine LAI in patients with schizophrenia, conducted by Teva Pharmaceuticals (NYSE:TEVA). Medicell reports that it will receive a...

February 10, 2025

Developments

FDA fast tracks Biodexa’s eRapa in FAP

Biodexa Pharmaceuticals (NASDAQ:BDRX) has announced that eRapa, a form of rapamycin being developed for the treatment of familial adenomatous polyposis (FAP), has been granted Fast Track Designation by the FDA...

February 10, 2025

Developments

Ekso Bionics names National Seating & Mobility as exclusive distributor of Ekso Indego Personal device within the complex rehabilitation technology industry

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) has named National Seating & Mobility (NSM), a leading provider of complex rehabilitation technology (CRT), mobility and accessibility solutions, as the exclusive Ekso...

February 10, 2025

Developments

Firefly congratulates company advisor, Dr. Christopher Wilson, on UW Faculty of Engineering Award for his work on superconducting quantum electronics

Firefly Neuroscience (NASDAQ:AIFF) has announced that Christopher Wilson, Ph.D., has been honored with the prestigious UW Faculty of Engineering Award by the University of Waterloo (UW) for his significant contributions...

February 7, 2025

Developments

Fennec unveils PEDMARQSI in Germany for cisplatin-induced hearing loss in children

Fennec Pharmaceuticals (NASDAQ:FENC; TSX:FRX) announced the commercial launch of PEDMARQSI sodium thiosulfate injection in Germany by Norgine Pharmaceuticals. The treatment is designed to prevent ototoxicity (permanent...

February 7, 2025

Developments

AIM addresses avian flu with follow-up clinical study of Ampligen and FluMist combo

AIM ImmunoTech (NYSE:AIM) has announced plans for a follow-up clinical study to evaluate the potential avian influenza combination therapy of its Ampligen with Astra Zeneca’s (NASDAQ: AZN) FluMist. According to AIM, the...

February 7, 2025

Developments

Lively X discussion about the clinical potential of Perimeter’s AI-driven, wide field OCT margin visualization technology during breast cancer surgeries helps drive stock

Perimeter Medical Imaging AI’s (TSX-V:PINK; OTC:PYNKF) ultra-high-res imaging tool for use during breast cancer surgeries was highlighted in a conversation today on X driven by renowned Silicon Valley venture...

February 4, 2025

Developments

Pyxis initiates new combination trial; expands existing monotherapy trial

Pyxis Oncology (NASDAQ:PYXS) has announced the initiation of a Phase 1/2 combination trial of its PYX-201 in conjunction with Merk’s (NYSE: MRK) anti-PD-1 therapy, KEYTRUDA (pembrolizumab), for the treatment of multiple...

February 4, 2025

Developments

uniQure completes enrollment for Phase 1/2a trial of gene therapy in Fabry disease

uniQure (NASDAQ:QURE) has announced the completion of enrollment for its Phase 1/2a trial of AMT-191 in patients with Fabry disease. The company also reports receiving a favorable recommendation from the Independent...

February 3, 2025

Developments

Vanda and Anaptys ink licencing agreement for commercialization of imsidolimab in GPP

Vanda Pharmaceuticals (NASDAQ:VNDA) and AnaptysBio (NASDAQ: ANAB) have announced an exclusive global licencing agreement granting Vanda the rights to commercialize imsidolimab, a treatment for generalized pustular...

February 3, 2025

Developments

Fractyl increases focus on key gene therapy programs

Fractyl Health (NASDAQ:GUTS) has announced plans to prioritize its REMAIN-1 pivotal study, advance its novel Rejuva gene therapy platform into first-in-human studies, and pause investment in its Revita programs for Type...

January 31, 2025

Subscribe